These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Leukocytoclastic vasculitis due to etanercept. Galaria NA; Werth VP; Schumacher HR J Rheumatol; 2000 Aug; 27(8):2041-4. PubMed ID: 10955351 [TBL] [Abstract][Full Text] [Related]
4. Comparison of the clinical characteristics of vasculitis occurring during anti-tumor necrosis factor treatment or not in rheumatoid arthritis patients. A systematic review of 2707 patients, 18 vasculitis. Guignard S; Gossec L; Bandinelli F; Dougados M Clin Exp Rheumatol; 2008; 26(3 Suppl 49):S23-9. PubMed ID: 18799049 [TBL] [Abstract][Full Text] [Related]
5. Digital vasculitis with eosinophilia possibly associated with etanercept therapy. Nakahigashi K; Egawa G; Miyachi Y; Kabashima K Acta Derm Venereol; 2014 Mar; 94(2):239-40. PubMed ID: 23824408 [No Abstract] [Full Text] [Related]
13. Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France. Saint Marcoux B; De Bandt M; Joint Bone Spine; 2006 Dec; 73(6):710-3. PubMed ID: 17127088 [TBL] [Abstract][Full Text] [Related]
14. Anti-TNF-alpha-induced systemic lupus syndrome. Debandt M; Vittecoq O; Descamps V; Le Loët X; Meyer O Clin Rheumatol; 2003 Feb; 22(1):56-61. PubMed ID: 12605321 [TBL] [Abstract][Full Text] [Related]
15. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital. Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328 [TBL] [Abstract][Full Text] [Related]
16. [Lupus like syndrome induced by treatment with anti TNFalpha (infliximab): report of three cases]. Benucci M; Nenci G; Cappelletti C; Manfredi M Recenti Prog Med; 2008; 99(7-8):363-6. PubMed ID: 18751615 [TBL] [Abstract][Full Text] [Related]
17. Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept. Mor A; Bingham CO; Barisoni L; Lydon E; Belmont HM J Rheumatol; 2005 Apr; 32(4):740-3. PubMed ID: 15801034 [TBL] [Abstract][Full Text] [Related]
18. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Ramos-Casals M; Brito-Zerón P; Muñoz S; Soria N; Galiana D; Bertolaccini L; Cuadrado MJ; Khamashta MA Medicine (Baltimore); 2007 Jul; 86(4):242-251. PubMed ID: 17632266 [TBL] [Abstract][Full Text] [Related]
19. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? Askling J; van Vollenhoven RF; Granath F; Raaschou P; Fored CM; Baecklund E; Dackhammar C; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Rantapää-Dahlqvist S; Saxne T; Klareskog L Arthritis Rheum; 2009 Nov; 60(11):3180-9. PubMed ID: 19877027 [TBL] [Abstract][Full Text] [Related]
20. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Lee JH; Slifman NR; Gershon SK; Edwards ET; Schwieterman WD; Siegel JN; Wise RP; Brown SL; Udall JN; Braun MM Arthritis Rheum; 2002 Oct; 46(10):2565-70. PubMed ID: 12384912 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]